Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.
about
Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivoSerum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor ImatinibCancer treatment with kinase inhibitors: what have we learnt from imatinib?Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Re-positioning protein-kinase inhibitors against schistosomiasis.
P2860
Q34395057-53CA04CF-938A-4A76-B518-B91090911B45Q34705820-34374E6E-05CE-43DC-96AD-6FE5932D8AF7Q35622440-3092656A-DA94-4611-8255-896918588BCBQ35816396-18E2D64A-9A5E-49D1-A35F-3F092B33A439Q35826342-79F3F22D-56C7-4FF8-95BF-B36EC048805CQ36037262-A57F4A68-EE91-4660-89E7-DE72A9FE6A00Q37696776-1A52A1D5-CE4A-49EB-929A-5F1EFE86901CQ38495042-A3CAFEC8-E3D8-4942-A46D-5295DE4DF917
P2860
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Differences between in vivo an ...... tained from leukemic patients.
@en
Differences between in vivo an ...... tained from leukemic patients.
@nl
type
label
Differences between in vivo an ...... tained from leukemic patients.
@en
Differences between in vivo an ...... tained from leukemic patients.
@nl
prefLabel
Differences between in vivo an ...... tained from leukemic patients.
@en
Differences between in vivo an ...... tained from leukemic patients.
@nl
P2093
P50
P356
P1476
Differences between in vivo an ...... btained from leukemic patients
@en
P2093
Enrico Pogliani
Fabio Rossi
Francesca Rossi
Gianmarco Corneo
Holger Ruchatz
Leonardo Scapozza
Lucia Tornaghi
Magda Verga
Pietro Pioltelli
Rosalind Gunby
P304
P356
10.1006/BCMD.2002.0526
P577
2002-05-01T00:00:00Z